XRTX

XORTX Therapeutics Inc. (NASDAQ:XRTX) is a Canadian biopharmaceutical company founded in Vancouver that focuses on developing therapies for progressive kidney diseases and related metabolic conditions. The company went public in September 2021 and operates as a clinical-stage biotechnology firm with three main drug candidates in various stages of development. XORTX specializes in targeting conditions such as autosomal dominant polycystic kidney disease, diabetic nephropathy, and complications related to elevated uric acid levels, including those associated with COVID-19 infections.